Celgene Corporation: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Celgene in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits

* Gain insight into Celgene's strategic outlook across the next 6 years* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights

Strategic insight into the prospects for King over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered

* Benchmark Celgene's performance against key rivals in the prescription pharmaceutical sector* See how Celgene, having experienced tremendous growth, will continue to see positive growth over the forecast period

[Studien Infos ausblenden]

Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Financial performance, 2003–15
Celgene: PharmaVitae forecasts at a glance
Strategic insight
Increased scale through M&A
Profit expansion post M&A
Revlimid remains central to Celgene’s performance to 2015
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly news update
Company introduction
Company sales
Company financials
Key products and competitors
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest comment
Latest prescription pharma product news
Q2 2010
Latest corporate news
Q3 2010
Q2 2010
Q1 2010
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Historical divestment generates capital
Minor acquisitions permit steady expansion
Pharmion acquisition is central to Celgene’s future growth
Gloucester Pharmaceuticals acquisition provides boost to launch portfolio
Abraxis acquisition completed in early Q4 2010
Current corporate structure
Pharmaceuticals
Collaborative agreements
Royalty revenue
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Product analysis
Product analysis, 2003–09
Product analysis, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009–15
Core analysis, 2009–15
Expiry analysis, 2009–15
Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
Operating costs and profit analysis
Operating costs and profit analysis, 2003–09
Operating cost ratio and profit margin analysis, 2003–09
Operating cost ratio and profit margin analysis, 2009–15
Operating costs and profit analysis, 2009–15
KEY PRODUCTS AND COMPETITORS
Key findings
Overview
Oncology
[Missing title]
Vidaza
Thalomid
Amrubicin
Abraxane
CC-4047 (pomalidomide)
Istodax
APPENDIX
R&D pipeline
References
Abbreviations

[Inhaltsverzeichnis ausblenden]